Poniard Pharma (PARD) Posts Q3 Loss of $0.29, In-Line with Estimates
Poniard Pharmaceuticals (NASDAQ: PARD) reports Q3 loss of $0.29, even with the analyst estimate of ($0.29).
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Signet Jewelers (SIG) Tops Q1 EPS by 5c; Guides Q2 Below the Street
- Frontline (FRO) Posts Surprise Q1 Profit
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
